Intrinsic value of Cantel Medical - CMD

Previous Close

$94.23

  Intrinsic Value

$33.06

stock screener

  Rating & Target

str. sell

-65%

Previous close

$94.23

 
Intrinsic value

$33.06

 
Up/down potential

-65%

 
Rating

str. sell

Our model is not good at valuating stocks of financial companies, such as CMD.

We calculate the intrinsic value of CMD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 4.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  15.90
  14.81
  13.83
  12.95
  12.15
  11.44
  10.79
  10.21
  9.69
  9.22
  8.80
  8.42
  8.08
  7.77
  7.49
  7.24
  7.02
  6.82
  6.64
  6.47
  6.33
  6.19
  6.07
  5.97
  5.87
  5.78
  5.70
  5.63
  5.57
  5.51
Revenue, $m
  892
  1,025
  1,166
  1,317
  1,477
  1,646
  1,824
  2,010
  2,205
  2,408
  2,620
  2,841
  3,071
  3,309
  3,557
  3,815
  4,083
  4,361
  4,650
  4,951
  5,265
  5,591
  5,930
  6,284
  6,653
  7,038
  7,439
  7,858
  8,296
  8,753
Variable operating expenses, $m
  755
  861
  974
  1,094
  1,222
  1,356
  1,498
  1,647
  1,802
  1,964
  2,089
  2,265
  2,448
  2,639
  2,836
  3,042
  3,255
  3,477
  3,708
  3,948
  4,198
  4,458
  4,729
  5,011
  5,305
  5,612
  5,932
  6,266
  6,615
  6,980
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  755
  861
  974
  1,094
  1,222
  1,356
  1,498
  1,647
  1,802
  1,964
  2,089
  2,265
  2,448
  2,639
  2,836
  3,042
  3,255
  3,477
  3,708
  3,948
  4,198
  4,458
  4,729
  5,011
  5,305
  5,612
  5,932
  6,266
  6,615
  6,980
Operating income, $m
  137
  164
  193
  223
  256
  290
  326
  364
  403
  444
  531
  576
  622
  671
  721
  773
  827
  884
  942
  1,003
  1,067
  1,133
  1,202
  1,273
  1,348
  1,426
  1,507
  1,592
  1,681
  1,774
EBITDA, $m
  238
  273
  311
  352
  394
  439
  487
  537
  589
  643
  699
  758
  820
  883
  950
  1,018
  1,090
  1,164
  1,241
  1,322
  1,405
  1,492
  1,583
  1,677
  1,776
  1,878
  1,986
  2,098
  2,214
  2,336
Interest expense (income), $m
  3
  7
  9
  12
  14
  17
  20
  23
  26
  30
  33
  37
  41
  45
  49
  54
  58
  63
  68
  73
  78
  84
  90
  96
  102
  108
  115
  122
  130
  137
  145
Earnings before tax, $m
  130
  155
  181
  209
  239
  270
  303
  337
  374
  411
  494
  535
  577
  621
  667
  715
  764
  816
  869
  925
  983
  1,043
  1,106
  1,171
  1,240
  1,311
  1,385
  1,463
  1,544
  1,628
Tax expense, $m
  35
  42
  49
  56
  64
  73
  82
  91
  101
  111
  133
  144
  156
  168
  180
  193
  206
  220
  235
  250
  265
  282
  299
  316
  335
  354
  374
  395
  417
  440
Net income, $m
  95
  113
  132
  153
  174
  197
  221
  246
  273
  300
  361
  390
  421
  454
  487
  522
  558
  596
  635
  675
  718
  762
  807
  855
  905
  957
  1,011
  1,068
  1,127
  1,189

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  912
  1,047
  1,191
  1,346
  1,509
  1,682
  1,863
  2,053
  2,252
  2,460
  2,677
  2,902
  3,136
  3,380
  3,634
  3,897
  4,170
  4,455
  4,750
  5,058
  5,378
  5,711
  6,057
  6,419
  6,796
  7,188
  7,599
  8,027
  8,474
  8,941
Adjusted assets (=assets-cash), $m
  912
  1,047
  1,191
  1,346
  1,509
  1,682
  1,863
  2,053
  2,252
  2,460
  2,677
  2,902
  3,136
  3,380
  3,634
  3,897
  4,170
  4,455
  4,750
  5,058
  5,378
  5,711
  6,057
  6,419
  6,796
  7,188
  7,599
  8,027
  8,474
  8,941
Revenue / Adjusted assets
  0.978
  0.979
  0.979
  0.978
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
  0.979
Average production assets, $m
  574
  659
  750
  847
  950
  1,059
  1,173
  1,293
  1,418
  1,549
  1,685
  1,827
  1,974
  2,128
  2,287
  2,453
  2,625
  2,804
  2,990
  3,184
  3,385
  3,595
  3,813
  4,041
  4,278
  4,525
  4,783
  5,053
  5,334
  5,628
Working capital, $m
  51
  58
  66
  75
  84
  94
  104
  115
  126
  137
  149
  162
  175
  189
  203
  217
  233
  249
  265
  282
  300
  319
  338
  358
  379
  401
  424
  448
  473
  499
Total debt, $m
  168
  213
  262
  313
  368
  425
  486
  549
  616
  685
  758
  833
  911
  993
  1,077
  1,165
  1,256
  1,351
  1,450
  1,553
  1,660
  1,771
  1,887
  2,008
  2,133
  2,265
  2,402
  2,545
  2,694
  2,850
Total liabilities, $m
  304
  350
  398
  449
  504
  562
  622
  686
  752
  822
  894
  969
  1,048
  1,129
  1,214
  1,302
  1,393
  1,488
  1,587
  1,689
  1,796
  1,907
  2,023
  2,144
  2,270
  2,401
  2,538
  2,681
  2,830
  2,986
Total equity, $m
  607
  697
  793
  896
  1,005
  1,120
  1,241
  1,368
  1,500
  1,638
  1,783
  1,933
  2,089
  2,251
  2,420
  2,595
  2,777
  2,967
  3,164
  3,368
  3,581
  3,803
  4,034
  4,275
  4,526
  4,788
  5,061
  5,346
  5,644
  5,955
Total liabilities and equity, $m
  911
  1,047
  1,191
  1,345
  1,509
  1,682
  1,863
  2,054
  2,252
  2,460
  2,677
  2,902
  3,137
  3,380
  3,634
  3,897
  4,170
  4,455
  4,751
  5,057
  5,377
  5,710
  6,057
  6,419
  6,796
  7,189
  7,599
  8,027
  8,474
  8,941
Debt-to-equity ratio
  0.280
  0.310
  0.330
  0.350
  0.370
  0.380
  0.390
  0.400
  0.410
  0.420
  0.430
  0.430
  0.440
  0.440
  0.450
  0.450
  0.450
  0.460
  0.460
  0.460
  0.460
  0.470
  0.470
  0.470
  0.470
  0.470
  0.470
  0.480
  0.480
  0.480
Adjusted equity ratio
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666
  0.666

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  95
  113
  132
  153
  174
  197
  221
  246
  273
  300
  361
  390
  421
  454
  487
  522
  558
  596
  635
  675
  718
  762
  807
  855
  905
  957
  1,011
  1,068
  1,127
  1,189
Depreciation, amort., depletion, $m
  101
  109
  119
  128
  139
  149
  161
  173
  185
  198
  168
  183
  197
  213
  229
  245
  263
  280
  299
  318
  339
  359
  381
  404
  428
  453
  478
  505
  533
  563
Funds from operations, $m
  196
  223
  251
  281
  313
  347
  382
  419
  458
  499
  529
  573
  619
  666
  716
  767
  820
  876
  934
  994
  1,056
  1,121
  1,189
  1,259
  1,333
  1,409
  1,489
  1,573
  1,660
  1,751
Change in working capital, $m
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  15
  16
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
Cash from operations, $m
  189
  215
  243
  272
  304
  337
  372
  409
  447
  487
  517
  560
  606
  653
  702
  752
  805
  860
  917
  976
  1,038
  1,102
  1,169
  1,239
  1,312
  1,387
  1,467
  1,549
  1,635
  1,725
Maintenance CAPEX, $m
  -50
  -57
  -66
  -75
  -85
  -95
  -106
  -117
  -129
  -142
  -155
  -168
  -183
  -197
  -213
  -229
  -245
  -263
  -280
  -299
  -318
  -339
  -359
  -381
  -404
  -428
  -453
  -478
  -505
  -533
New CAPEX, $m
  -78
  -85
  -91
  -97
  -103
  -109
  -114
  -120
  -125
  -131
  -136
  -142
  -148
  -153
  -159
  -166
  -172
  -179
  -186
  -194
  -201
  -210
  -218
  -227
  -237
  -247
  -258
  -269
  -281
  -294
Cash from investing activities, $m
  -128
  -142
  -157
  -172
  -188
  -204
  -220
  -237
  -254
  -273
  -291
  -310
  -331
  -350
  -372
  -395
  -417
  -442
  -466
  -493
  -519
  -549
  -577
  -608
  -641
  -675
  -711
  -747
  -786
  -827
Free cash flow, $m
  61
  73
  86
  100
  116
  133
  152
  172
  192
  214
  226
  250
  275
  302
  329
  358
  388
  419
  451
  484
  518
  554
  592
  630
  670
  712
  756
  801
  849
  898
Issuance/(repayment) of debt, $m
  42
  45
  48
  52
  55
  58
  61
  64
  66
  69
  72
  75
  78
  81
  85
  88
  91
  95
  99
  103
  107
  111
  116
  121
  126
  131
  137
  143
  149
  156
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  42
  45
  48
  52
  55
  58
  61
  64
  66
  69
  72
  75
  78
  81
  85
  88
  91
  95
  99
  103
  107
  111
  116
  121
  126
  131
  137
  143
  149
  156
Total cash flow (excl. dividends), $m
  103
  118
  134
  152
  171
  191
  212
  235
  259
  284
  298
  325
  354
  383
  414
  446
  479
  514
  549
  587
  625
  665
  707
  751
  796
  844
  893
  944
  998
  1,054
Retained Cash Flow (-), $m
  -83
  -90
  -96
  -103
  -109
  -115
  -121
  -127
  -133
  -138
  -144
  -150
  -156
  -162
  -169
  -175
  -182
  -189
  -197
  -205
  -213
  -222
  -231
  -241
  -251
  -262
  -273
  -285
  -298
  -311
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  8
  10
  11
  13
  14
  16
  18
  20
  22
  24
  26
  29
  31
  34
  36
  39
  42
  45
  48
  51
  54
  58
  61
  65
  69
  73
  77
  82
  86
  91
Cash available for distribution, $m
  20
  28
  38
  49
  62
  76
  92
  108
  126
  145
  154
  175
  198
  221
  245
  271
  297
  324
  352
  382
  412
  444
  476
  510
  545
  582
  620
  659
  700
  743
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  19
  26
  33
  40
  48
  55
  62
  68
  73
  76
  73
  75
  75
  74
  72
  69
  65
  60
  54
  49
  43
  37
  31
  26
  21
  17
  13
  10
  8
  6
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company's operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company's Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company's Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.

FINANCIAL RATIOS  of  Cantel Medical (CMD)

Valuation Ratios
P/E Ratio 55.4
Price to Sales 5.1
Price to Book 7.5
Price to Tangible Book
Price to Cash Flow 36.4
Price to Free Cash Flow 48.5
Growth Rates
Sales Growth Rate 15.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 42.1%
Cap. Spend. - 3 Yr. Gr. Rate 14%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 24%
Total Debt to Equity 24%
Interest Coverage 36
Management Effectiveness
Return On Assets 9.9%
Ret/ On Assets - 3 Yr. Avg. 9.4%
Return On Total Capital 11.6%
Ret/ On T. Cap. - 3 Yr. Avg. 11.1%
Return On Equity 14.5%
Return On Equity - 3 Yr. Avg. 13.6%
Asset Turnover 1
Profitability Ratios
Gross Margin 47.8%
Gross Margin - 3 Yr. Avg. 46.5%
EBITDA Margin 18.4%
EBITDA Margin - 3 Yr. Avg. 18.3%
Operating Margin 14.3%
Oper. Margin - 3 Yr. Avg. 14.3%
Pre-Tax Margin 13.8%
Pre-Tax Margin - 3 Yr. Avg. 13.8%
Net Profit Margin 9.2%
Net Profit Margin - 3 Yr. Avg. 8.9%
Effective Tax Rate 33%
Eff/ Tax Rate - 3 Yr. Avg. 35.3%
Payout Ratio 8.5%

CMD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CMD stock intrinsic value calculation we used $770 million for the last fiscal year's total revenue generated by Cantel Medical. The default revenue input number comes from 2017 income statement of Cantel Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CMD stock valuation model: a) initial revenue growth rate of 15.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CMD is calculated based on our internal credit rating of Cantel Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cantel Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CMD stock the variable cost ratio is equal to 85.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CMD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Cantel Medical.

Corporate tax rate of 27% is the nominal tax rate for Cantel Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CMD stock is equal to 1.1%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CMD are equal to 64.3%.

Life of production assets of 10 years is the average useful life of capital assets used in Cantel Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CMD is equal to 5.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $524 million for Cantel Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 42 million for Cantel Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cantel Medical at the current share price and the inputted number of shares is $4.0 billion.

COMPANY NEWS

▶ Cantel Medical Takes Its Foot off the Gas   [Jun-01-18 04:12PM  Motley Fool]
▶ Cantel: Fiscal 3Q Earnings Snapshot   [08:10AM  Associated Press]
▶ Earnings Calendar, Analyst Estimates And Stocks To Watch   [May-24-18 10:05AM  Investor's Business Daily]
▶ Earnings Season Watch List: Cantel Medical   [03:00AM  Investor's Business Daily]
▶ Cantel Medical leases Sleep Numbers former headquarters   [May-17-18 01:44PM  American City Business Journals]
▶ Cantel Medical Acquires Aexis Medical   [Mar-21-18 08:30AM  PR Newswire]
▶ Cantel Medical Acquires Aexis Medical   [08:30AM  CNW Group]
▶ Cantel posts 2Q profit   [08:27AM  Associated Press]
▶ Cantel Medical Corp. Keeps Pace on Its Goal   [Dec-08-17 04:15PM  Motley Fool]
▶ Cantel posts 1Q profit   [Dec-07-17 08:23AM  Associated Press]
▶ Cantel Medical Just Within Buy Range As Earnings Approach   [Dec-05-17 03:00AM  Investor's Business Daily]
▶ No. 1-Ranked Medical Stock In Buy Zone With Earnings Due   [Nov-20-17 04:08PM  Investor's Business Daily]
▶ These 4 Stocks Hit Buy Points; This New IPO Soars Late: S&P 500 Futures   [Nov-15-17 12:25AM  Investor's Business Daily]
▶ Cantel posts 4Q profit   [Sep-28-17 09:41PM  Associated Press]
▶ Stocks Showing Improved Relative Strength: Cantel Medical   [03:00AM  Investor's Business Daily]
▶ Stocks With Rising Relative Strength: Cantel Medical   [Sep-20-17 03:00AM  Investor's Business Daily]
▶ This Medical Device Maker Is Now Outperforming 96% Of All Stocks   [Sep-18-17 10:49AM  Investor's Business Daily]
▶ Cantel Medical to Acquire BHT Group in Germany   [Jul-31-17 08:00AM  PR Newswire]
▶ ETFs with exposure to Cantel Medical Corp. : June 9, 2017   [Jun-09-17 01:22PM  Capital Cube]
▶ Cantel Medical Corp. Gives the Bottom Line a Boost   [Jun-08-17 04:21PM  Motley Fool]
▶ Cantel posts 3Q profit   [08:28AM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.